Investment Rating - The investment rating for the company is "Buy" and the rating has been maintained [4][11]. Core Insights - The company has shown significant growth with a revenue of 2.375 billion yuan in 2025, marking a year-on-year increase of 135.27%. The net profit reached 644 million yuan, a substantial increase from the previous year, indicating the first annual profit for the company [3][11]. - The revenue structure is shifting from a single product focus to a dual-driven model of commercial sales and technology licensing, with drug sales contributing approximately 60.73% and technology licensing accounting for about 38.07% of total revenue [3][11]. - The core product, Acalabrutinib, continues to see rapid commercialization, achieving sales of 1.41 billion yuan, a year-on-year growth of 40.99%. The product's inclusion in medical insurance has significantly improved patient accessibility [3][6][11]. Financial Performance - In 2025, the company reported a net cash flow from operating activities of 84 million yuan, and R&D expenses were 952 million yuan, reflecting a year-on-year increase of 16.82% [3][11]. - The company expects revenues of 2.106 billion yuan, 2.633 billion yuan, and 3.258 billion yuan for 2026, 2027, and 2028 respectively, with a projected net profit of -0.85 million yuan, 116.56 million yuan, and 377.17 million yuan for the same years [11][13]. Product Development - The company has initiated commercialization of Tafasitamab and received NMPA approval for Zolbetuximab, expanding its product matrix and opening new revenue streams [6][10]. - The BCL-2 inhibitor Mesutoclax is progressing through clinical trials and is expected to become a strategic pillar in the hematology sector, with multiple key trials underway [7][11]. - The company is also deepening its layout in the autoimmune disease field, with ongoing clinical developments for Acalabrutinib and TYK2 products across various indications [8][9]. Market Position and Future Outlook - The company is enhancing its commercialization capabilities, which is expected to support revenue growth in the hematology sector and strengthen its long-term global value [6][11]. - The ADC platform is showing significant progress, with multiple candidates in clinical development, providing a continuous growth engine for the company [10][11].

Investment Rating - The investment rating for the company is "Buy" and the rating has been maintained [3][4]. Core Insights - The company has shown significant growth with a total revenue of 2.375 billion yuan in 2025, representing a substantial year-on-year increase of 135.27%. The net profit reached 644 million yuan, marking a turnaround from losses in the previous year [3][11]. - The revenue structure is evolving from a single product focus to a dual-driven model of commercial sales and technology licensing, with drug sales contributing approximately 60.73% and technology licensing accounting for about 38.07% of total revenue [3][11]. - The core product, Aobutinin, continues to experience rapid growth, achieving commercial revenue of 1.41 billion yuan, a year-on-year increase of 40.99%. The internationalization of Aobutinin is also progressing, with approvals in Singapore and submissions in Australia [3][6]. Financial Performance - In 2025, the company achieved a net profit of 644 million yuan, a significant increase from a loss of 10.97 million yuan in the previous year. The operating cash flow turned positive at 84 million yuan [3][11]. - The company expects revenues of 2.106 billion yuan, 2.633 billion yuan, and 3.258 billion yuan for 2026, 2027, and 2028 respectively, with corresponding net profits projected at -0.85 million yuan, 116.56 million yuan, and 377.17 million yuan [11][13]. Product Development and Pipeline - The company has initiated commercialization of Tafasitamab and received NMPA approval for Zolbetuximab, expanding its product matrix and revenue potential [6][10]. - The BCL-2 inhibitor Mesutoclax is progressing through clinical trials and is expected to become a strategic pillar in the hematology field, with multiple key trials underway [7][11]. - The company is also deepening its layout in the autoimmune disease sector, with ongoing clinical developments for Aobutinin and TYK2 products across various indications [8][9]. Market Position and Future Outlook - The company is positioned to leverage its growing commercial capabilities and product pipeline to sustain revenue growth in the hematology sector and expand into solid tumors [6][10]. - The strategic focus on multiple innovative projects, including small molecules and ADCs, is expected to solidify the company's long-term growth trajectory [11][10].

Investment Rating - The report assigns a positive investment rating to the company, indicating a favorable outlook for the next six months [1]. Core Insights - The company has turned profitable for the first time, with a reported net profit of 642.47 million HKD in 2025, marking a significant increase of 245.81% compared to the previous year [7]. - The revenue for 2025 reached 2.37491 billion HKD, reflecting a growth rate of 135.27% [2]. - Strong sales growth of the drug Aobutini, which generated 1.41 billion HKD in 2025, up by 41% [7]. - The company has successfully licensed Aobutini to Zenas BioPharma, with a total transaction amount exceeding 2 billion USD, setting a record for external licensing in China's small molecule field [7]. - The company’s pipeline is entering a harvest phase, with multiple potential products progressing through clinical trials [7]. Financial Summary - The projected revenues for 2026, 2027, and 2028 are estimated at 20.2 billion HKD, 24.4 billion HKD, and 28.4 billion HKD respectively [9]. - The expected earnings per share (EPS) for 2026, 2027, and 2028 are 0.26 HKD, 0.29 HKD, and 0.32 HKD respectively [2]. - The net asset return (ROE) is projected to be 5.53% in 2026, increasing to 6.18% by 2028 [2]. - The price-to-earnings (PE) ratio is expected to decrease from 48.37 in 2026 to 38.21 in 2028 [2]. Product Pipeline and Development - Aobutini is expected to submit a market application for ITP in the first half of 2026, with several other clinical trials for various indications also underway [7]. - The company has two TYK2 inhibitors, with ongoing clinical trials for multiple conditions, including moderate to severe atopic dermatitis and vitiligo [7]. - The company is advancing multiple antibody-drug conjugate (ADC) projects, with IND approvals and clinical trials planned for 2026 [7].

Summary of the Conference Call for 诺诚健华 (Nocera Biopharma) Company Overview - **Company**: 诺诚健华 (Nocera Biopharma) - **Industry**: Biotechnology, focusing on oncology and autoimmune diseases Key Financial Highlights - **2025 Financial Performance**: - Total revenue reached 23.75 billion RMB, a year-on-year increase of 135.3% [2][4] - Net profit of 6.4 billion RMB, marking the first profitable year [2][4] - Cash reserves stood at 78 billion RMB, with positive operating cash flow of 84 million RMB [2][4] - **Sales Growth Expectations for 2026**: - Anticipated drug sales revenue growth of at least 35% [2][6] - Sales expense ratio expected to decrease to 35%-40% [2][23] Product Development and Commercialization - **Key Products**: - **奥布替尼 (Obutinin)**: - Approved for multiple indications including CLL/SLL and MCL, with significant sales growth expected [3][5][23] - NDA submission for ITP expected in H1 2026 [2][11] - **坦西妥单抗 (Tansizumab)**: - Approved for DLBCL, showing superior efficacy in combination therapies [7] - **左来曲替尼 (Zuranolone)**: - Approved for NTRK fusion-positive solid tumors, with promising clinical outcomes [17][20] - **莫斯妥昔单抗 (Mosunetuzumab)**: - Demonstrated high ORR of 84% in MCL, with plans for market submission by 2027 [2][8] Research and Development Pipeline - **Oncology Pipeline**: - Over 10 products in late-stage clinical trials, with multiple approvals expected in the next 2-3 years [3][4] - ADC platform showing promise with B7-H3 ADC (B794) and Claudin-17 ADC (B208) [18][20] - **Autoimmune Disease Pipeline**: - Five products in clinical stages, including ICP-332 and ICP-488 targeting various autoimmune conditions [10][14] - Significant market potential for SLE and other indications, with expected data readouts in 2026 [11][30] Strategic Collaborations - **Partnerships**: - Strategic collaborations with Xenios BioPharma and Premium for asset licensing and development [3][4] - Ongoing discussions for potential new partnerships in 2026 [32] Market Potential and Competitive Landscape - **Market Size**: - The market for Mosunetuzumab in lymphoma and leukemia is projected to exceed 20 billion USD [9] - Significant unmet needs in MDS and AML, with plans for clinical development [25][27] - **Competitive Advantages**: - Unique drug design and mechanisms of action for BCL-2 inhibitors and TYK2 inhibitors [13][14] - Strong safety profiles and efficacy in clinical trials compared to existing therapies [8][26] Future Outlook - **2026 Expectations**: - Continued revenue growth driven by existing products and new launches [34] - Anticipated key milestones in clinical trials and potential new drug applications [34] - Focus on expanding R&D capabilities and exploring innovative treatment options [34] This summary encapsulates the critical insights from the conference call, highlighting the company's financial performance, product pipeline, strategic collaborations, and future outlook in the biotechnology sector.

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 InnoCare Pharma Limited 諾誠健華醫藥有限公司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：9969） 海外監管公告 本公告乃諾誠健華醫藥有限公司（「本公司」）根據香港聯合交易所有限公司證 券上市規則第13.10B條作出。 茲載列本公司於上海證券交易所網站刊登之《董事會決議公告》、《2025年年度 報告》、《2025年年度報告摘要》、《2025年度審計報告》、《2025年度非經營性資 金佔用及其他關聯資金往來情況的專項說明》、《2025年度持續督導現場檢查報 告》、《2025年度內部控制評價報告》、《內部控制審計報告》、《2025年度「提質 增效重回報」行動方案的年度評估報告及2026年度「提質增效重回報」行動方案》、 《董事會審核委員會2025年度履職報告》、《董事會關於會計師事務所履職情況 的評估報告》、《董事會審核委員會對會計師事務所履行監督職 ...

InnoCare Pharma 2025 Annual Results Earnings Call Stock Code: 09969.HK, 688428.SH March 25, 2026 1 Disclaimer These materials are for information purposes only and do not constitute or form part of an offer or invitation to sell or issue or the solicitation of an offer or invitation to buy or subscribe for securities of InnoCare Pharma Limited (the "Company") or any of its holding company or subsidiaries in any jurisdiction. No part of these materials shall form the basis of or be relied upon in connection ...

Investment Rating - The industry investment rating is "Outperform the Market," indicating an expected performance exceeding the market by more than 5% within the next six months [54]. Core Insights - The global population affected by multiple sclerosis (MS) is substantial, with over 2 million patients worldwide, particularly prevalent in Europe and the United States. The disease primarily affects individuals aged 20-40, with a significant economic burden, as the costs in the U.S. alone exceed $24 billion [3][6]. - Current therapies for MS include CD20 monoclonal antibodies, which dominate the market. Notably, Roche's Ocrelizumab is projected to generate approximately $9 billion in sales by 2025, while Novartis's Ofatumumab is expected to reach $4.426 billion [3][17]. - BTK inhibitors are emerging as a promising new treatment option for MS, targeting both adaptive and innate immune mechanisms. Several companies, including Sanofi, Roche, and Novartis, are advancing their BTK inhibitors through clinical trials, with significant results expected in the near future [3][24][30][34]. Summary by Sections 1. Global Patient Population of Multiple Sclerosis - MS is characterized by inflammatory demyelination in the central nervous system, with symptoms including vision loss and motor impairment. The disease typically begins between the ages of 20 and 40, with a global prevalence of approximately 2.99 million patients as of 2022 [6][10]. 2. BTK Inhibitors as a New Treatment Option - BTK inhibitors are significant due to their ability to modulate B cell and myeloid cell activity, making them potential treatments for MS. Several BTK inhibitors are in clinical development, with promising results from trials conducted by companies like Sanofi and Roche [24][30][34]. 3. Investment Recommendations - The report recommends focusing on companies with advanced pipelines in the MS treatment space, particularly those with BTK inhibitors in late-stage clinical trials, such as Novartis's Remibrutinib and Innovent Biologics's Orelabrutinib [50].

Investment Rating - The report maintains a "Positive" outlook for the pharmaceutical and biotechnology industry [5] Core Viewpoints - Short-term fluctuations do not change the long-term growth trajectory of the innovative drug sector. Despite recent market volatility, the underlying logic for medium to long-term growth remains intact, driven by globalization, technological breakthroughs, and industry upgrades [8][12] - The focus has shifted from "can we go global" to "what progress has been made after going global," emphasizing the importance of overseas clinical deployment and milestone achievements for innovative drugs [13][14] - Breakthroughs in frontier technologies, particularly in small nucleic acids and CAR-T therapies, position Chinese companies to become core global assets [18][20] - The commercialization of innovative drugs is expected to lead to a profitability inflection point, with key companies entering a positive cycle of product volume growth and reinvestment in R&D [22] Summary by Sections 1. Short-term Fluctuations, Long-term Growth - The innovative drug sector has experienced significant volatility due to concentrated expectations and emotions, but the long-term growth trend remains unchanged [8][12] - The valuation of leading companies has reached reasonable levels, suggesting potential investment opportunities as market sentiment stabilizes [12] 1.1 Focus on Globalization Progress - The emphasis has shifted to the progress of products in overseas clinical trials, with a focus on key data readouts and milestone achievements [13][14] - Domestic bispecific antibodies are accelerating their global clinical trials, becoming core trading assets in the context of expiring patents for PD-(L)1 products [13] 1.2 Breakthroughs in Frontier Technologies - Chinese companies are leading in small nucleic acids and CAR-T therapies, with significant advancements in delivery technologies expanding treatment options beyond rare diseases [18] - In vivo CAR-T therapies have shown preliminary clinical effectiveness, with a growing number of transactions indicating a shift towards mainstream adoption [20] 1.3 Commercialization Driving Profitability - Leading innovative drug companies are entering a cycle of product volume growth that supports R&D reinvestment, with expectations for exceeding market performance in 2023 [22] - The upcoming earnings period in March-April 2026 is seen as a critical validation point for the sector [22] 2. Global New Drugs: Highlights in Autoimmunity and Oncology - The report highlights the approval of the world's first PD-L1/TGF-β bispecific antibody, showcasing the R&D capabilities of domestic companies [26][27] - The successful launch of innovative drugs in critical therapeutic areas reflects the growing strength of domestic pharmaceutical companies in addressing unmet medical needs [26][27]

Group 1 - The core innovation vitality of the pharmaceutical industry in the Zhongguancun Life Science Park continues to thrive, with 22 innovative drugs approved for clinical trials by 2025, focusing on breakthroughs in oncology and rare diseases [1][4] - Innovative drug company Nocare Biopharma has completed patient enrollment for its Phase III clinical trial of the new BCL2 inhibitor mesutoclax combined with BTK inhibitor ibrutinib for treating chronic lymphocytic leukemia/small lymphocytic lymphoma, marking a significant step towards market launch [2][3] - BeiGene, a leading innovative drug company from the park, announced its first annual profit since establishment, driven by the strong sales of its core innovative drug products, including a global sales revenue of 28.067 billion yuan for its drug zanubrutinib, which saw a 49% year-on-year increase [4] Group 2 - The Zhongguancun Life Science Park has showcased its 2025 innovation report, highlighting 22 innovative drugs in clinical trials across various cutting-edge fields, including rare diseases, mRNA vaccines, and cell therapy, with several achieving dual clinical trial approvals in China and the U.S. [4][5] - The rare disease drug TollB-001 developed by TuoLing BoTai has received clinical trial approvals in both China and the U.S., targeting systemic sclerosis and offering new treatment options for rare disease patients [5] - The GLP-1/FGF21 dual agonist ZT003 has been approved for clinical trials in the U.S., representing a breakthrough in metabolic disease treatment with multiple benefits including blood sugar control and weight loss [6]

Core Insights - BeiGene has become a focal point in China's innovative drug sector, achieving significant revenue and profit growth driven by its core products and strategic market positioning [1][11] - The company's total global revenue for 2025 reached $5.3 billion, marking a 40% year-on-year increase, primarily due to the strong performance of its flagship product, Brukinsa (Zebutinib) [1][11] - Brukinsa generated $3.9 billion in global sales, a 49% increase year-on-year, solidifying its role as the main driver of revenue growth [1][11] Revenue Growth - The two main self-developed products contributed over 90% of total revenue, with Brukinsa accounting for more than 70% [2][12] - The product matrix's synergy and the launch of new products, such as the BCL-2 inhibitor, have established a sustainable growth model for the company [2][12] Market Positioning - Brukinsa is recognized as the most widely approved BTK inhibitor globally, benefiting from its efficacy and safety, which has helped it secure a leading market position [3][13] - The BTK inhibitor market is experiencing a structural shift, with new-generation products gaining traction as first-generation products lose market share, providing a favorable environment for Brukinsa's growth [3][14] Product Development - The approval of the BCL-2 inhibitor, BeiGene's new product, in January 2026, fills a gap in the domestic treatment landscape and is expected to contribute to future revenue growth [5][15] - The steady growth of the other core product, Tislelizumab (Breztri), in the solid tumor space, further supports the company's dual-driven growth strategy [4][15] Industry Trends - The global demand for oncology drugs is expanding, driven by an aging population and increasing healthcare awareness, creating a broad market opportunity for innovative drug companies [6][16] - The competitive landscape in the innovative drug sector is intensifying, with both domestic and international companies vying for market share, leading to a phenomenon of "Matthew Effect" where established players gain more advantages [6][17] Future Outlook - The company projects total revenue for 2026 to be between $6.2 billion and $6.4 billion, indicating continued growth potential [9][20] - Future growth will rely on multiple product launches and expansions into new therapeutic areas, including autoimmune diseases, which could open new revenue streams [8][19]